Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leitlinienreport der S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome“.
Groß S, Bitzer M, Blödt S, Fischer N, Follmann M, Freudenberger P, Langer T, Lynen Jansen P, Nothacker M, Steubesand N, Galle PR, Malek NP. Groß S, et al. Among authors: malek np. Z Gastroenterol. 2024 Jan;62(1):e162-e212. doi: 10.1055/a-2189-6197. Epub 2024 Jan 9. Z Gastroenterol. 2024. PMID: 38195104 Free article. German. No abstract available.
Leitlinienreport der S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome – Version 3.0 – Juli 2022, AWMF-Registernummer: 032/053OL.
Groß S, Bitzer M, Blödt S, Follmann M, Langer T, Freudenberger P, Steubesand N, Lorenz P, Lynen Jansen P, Galle PR, Malek NP. Groß S, et al. Among authors: malek np. Z Gastroenterol. 2023 Apr;61(4):e157-e171. doi: 10.1055/a-1975-0570. Epub 2023 Apr 11. Z Gastroenterol. 2023. PMID: 37040778 Free article. German. No abstract available.
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.
Maier D, Vehreschild JJ, Uhl B, Meyer S, Berger-Thürmel K, Boerries M, Braren R, Grünwald V, Hadaschik B, Palm S, Singer S, Stuschke M, Juárez D, Delpy P, Lambarki M, Hummel M, Engels C, Andreas S, Gökbuget N, Ihrig K, Burock S, Keune D, Eggert A, Keilholz U, Schulz H, Büttner D, Löck S, Krause M, Esins M, Ressing F, Schuler M, Brandts C, Brucker DP, Husmann G, Oellerich T, Metzger P, Voigt F, Illert AL, Theobald M, Kindler T, Sudhof U, Reckmann A, Schwinghammer F, Nasseh D, Weichert W, von Bergwelt-Baildon M, Bitzer M, Malek N, Öner Ö, Schulze-Osthoff K, Bartels S, Haier J, Ammann R, Schmidt AF, Guenther B, Janning M, Kasper B, Loges S, Stilgenbauer S, Kuhn P, Tausch E, Runow S, Kerscher A, Neumann M, Breu M, Lablans M, Serve H. Maier D, et al. Eur J Epidemiol. 2023 May;38(5):573-586. doi: 10.1007/s10654-023-00990-w. Epub 2023 Apr 5. Eur J Epidemiol. 2023. PMID: 37017830 Free PMC article.
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, Liebmann A, Haack TB, Neumann M, Bonzheim I, Forschner A, Kopp HG, Herster F, Hartkopf A, Bitzer M, Malek NP, Brecht IB, Ruhm K, Möller Y, Löwenheim H, Ossowski S, Rieß OH, Schroeder C. Roggia C, et al. Among authors: malek np. Eur J Cancer. 2023 Jan;179:48-55. doi: 10.1016/j.ejca.2022.11.003. Epub 2022 Nov 8. Eur J Cancer. 2023. PMID: 36495689
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Hackenbruch C, Bauer J, Heitmann JS, Maringer Y, Nelde A, Denk M, Zieschang L, Kammer C, Federmann B, Jung S, Martus P, Malek NP, Nikolaou K, Salih HR, Bitzer M, Walz JS. Hackenbruch C, et al. Among authors: malek np. Front Oncol. 2024 Mar 28;14:1367450. doi: 10.3389/fonc.2024.1367450. eCollection 2024. Front Oncol. 2024. PMID: 38606105 Free PMC article.
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE).
Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek HS, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. Dörner L, et al. Neurooncol Pract. 2024 Jan 20;11(3):336-346. doi: 10.1093/nop/npae002. eCollection 2024 Jun. Neurooncol Pract. 2024. PMID: 38737615 Free PMC article.
The German Network for Personalized Medicine to enhance patient care and translational research.
Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. Illert AL, et al. Among authors: malek np. Nat Med. 2023 Jun;29(6):1298-1301. doi: 10.1038/s41591-023-02354-z. Nat Med. 2023. PMID: 37280276 No abstract available.
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S, Kleinhenz F, Shevchenko E, Stahl A, Rasen Y, Geisler C, Ruhm K, Klaumuenzer M, Kronenberger T, Laufer SA, Sundberg-Malek H, Bui KC, Horger M, Biskup S, Schulze-Osthoff K, Templin M, Malek NP, Poso A, Bitzer M. Spahn S, et al. Among authors: malek np. Nat Commun. 2024 Feb 12;15(1):1287. doi: 10.1038/s41467-024-45247-6. Nat Commun. 2024. PMID: 38346946 Free PMC article.
186 results